Latest close
$8.65
As of Oct 16, 2026
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Deep Track Capital | 0.32% | 5,740,850 | HELD |
| Torray Funds | 0.25% | 477,455 | ADDED (+59.7%) |
| RTW Investments | 0.22% | 6,635,793 | ADDED (+0.9%) |
| Baker Bros. Advisors | 0.05% | 2,499,338 | ADDED (+327.4%) |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end. Fund counts here aggregate every share class mapped to this ticker; research headlines cite filer counts as they stood at publication, so a count here can differ from a headline by a holder (see Methodology, "How holder counts are counted").
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
| Institutions holding | 159 of 8,857 filers |
| Long-only filers among them | 157 |
| Change vs 2026 Q1 | +8 net · 154 entered · 146 exited |
| Shares reported, all filers | 95,100,950 |
| Reported value, all filers | $364.4M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2024 | $10.0M |
| Net income · FY2025 | $-209.5M |
| Total assets · FY2025 | $246.4M |
| Shares outstanding | 90,563,441 |
| Market cap (at latest close) | $783.4M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 7, 2026. Shares outstanding as reported Aug 3, 2026.
| Shares short · Sep 15, 2026 | 18,028,616 |
| Share of shares outstanding | 19.91% |
| Days to cover | 6.52 |
Shares short at recent settlements — Jun 30, 2026: 24.1M · Jul 15, 2026: 20.1M · Jul 31, 2026: 19.8M · Aug 14, 2026: 18.9M · Aug 31, 2026: 18.3M · Sep 15, 2026: 18.0M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.
| Shares failed to deliver · Sep 15, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Sep 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jun 30, 2026: 81K · Jul 15, 2026: 256 · Jul 31, 2026: 0 · Aug 14, 2026: 3K · Aug 31, 2026: 59 · Sep 15, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 2 sales by 2 insiders ($8.0K).
Source: SEC Form 4 filings, as of Oct 18, 2026. Open-market transactions only.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Oct 3, 2026).
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%
Key figures
· Distress Risk (Altman Z″) — Z″-Score: -15.71 · Working capital / assets: 0.61 · Retained earnings / assets: -4.73 · EBIT / assets: -0.69 · Equity / liabilities: 0.30
· Excess Accruals (Sloan) — Accruals ratio: -25.3% · Net income: $-209.5M · Operating cash flow: $-137.5M · Investing cash flow: $-9.6M
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold VSTM: TANGO THERAPEUTICS INC (TNGX) · STRUCTURE THERAPEUTICS INC (GPCR) · CYTOKINETICS INC (CYTK) · AVALO THERAPEUTICS INC (AVTX) · Immunovant, Inc. (IMVT) · XENCOR INC (XNCR) · Alkermes plc. (ALKS) · COMPASS Pathways plc (CMPS) · IMMUNOCORE HOLDINGS PLC-ADR (IMCR) · DANAHER CORP /DE/ (DHR).
Filings audit: every filing lens on Verastem, Inc. (VSTM), scored — GetCoattail Research.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.